img

Global Recombinant Insulin Analogue Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Recombinant Insulin Analogue Market Insights, Forecast to 2034

Recombinant insulin analogues are not easy to cause heterogenous allergic reaction in patients, with small side effects; It can simulate the physiological insulin secretion curve of human body, accurately adjust the blood glucose concentration of human body, reduce the risk of hypoglycemia, and further improve the safety and effectiveness.
Global Recombinant Insulin Analogue market is expected to reach to US$ million in 2024, with a positive growth of %, compared with US$ million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Recombinant Insulin Analogue industry is evaluated to reach US$ million in 2029. The CAGR will be % during 2024 to 2029.
Globally, Recombinant Insulin Analogue key manufacturers include Novo Nordisk A/S, Eli Lilly and Company, Sanofi, Gan & Lee Pharmaceuticals Co., Ltd, The United Laboratories International Holdings Limited and Tonghua Dongbao Pharmaceutical Co., Ltd, etc. Novo Nordisk A/S, Eli Lilly and Company, Sanofi are top 3 players and held % sales share in total in 2022.
When considering the consumption regions, % volume of Recombinant Insulin Analogue were sold to North America, Europe and Asia Pacific in 2022. Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029 and the sales share will be % in 2029. Moreover, China, plays a key role in the whole Recombinant Insulin Analogue market and estimated to attract more attentions from industry insiders and investors.
Recombinant Insulin Analogue can be divided into Quick-Acting, Medium Effect, Long-Lasting and Super Long-Acting, etc. Quick-Acting is the mainstream product in the market, accounting for % sales share globally in 2022 and the proportion will be % in 2029.
Recombinant Insulin Analogue is widely used in various fields, such as Type 1 Diabetes and Type 2 Diabetes, etc. Type 1 Diabetes provides greatest supports to the Recombinant Insulin Analogue industry development. In 2022, global % sales of Recombinant Insulin Analogue went into Type 1 Diabetes filed and the proportion will reach to % in 2029.
Report Covers
This report presents an overview of global Recombinant Insulin Analogue market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Recombinant Insulin Analogue market with multiple angles. Items like regional sales, revenue from 2018 to 2029 and manufacturers’ sales, price, revenue and gross margin from 2018 to 2024 are analyzed. In addition, sales and revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Manufacturers, Type, Application and Regions Listed in the Report



By Company


Novo Nordisk A/S
Eli Lilly and Company
Sanofi
Gan & Lee Pharmaceuticals Co., Ltd
The United Laboratories International Holdings Limited
Tonghua Dongbao Pharmaceutical Co., Ltd
Segment by Type
Quick-Acting
Medium Effect
Long-Lasting
Super Long-Acting

Segment by Application


Type 1 Diabetes
Type 2 Diabetes

Segment by Region


US & Canada
U.S.
Canada
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Europe
Germany
France
U.K.
Italy
Russia
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue and sales volume analysis from 2018 to 2029
Chapter 3Manufacturers’ sales, revenue and price analysis, including manufacturers’ Recombinant Insulin Analogue plant distribution, commercial date of Recombinant Insulin Analogue, product type offered, Mergers & Acquisitions and expansion activities.
Chapter 4Product sales, revenue and price analysis by type from 2018 to 2029 globally
Chapter 5Product sales, revenue and price analysis by application from 2018 to 2029 globally
Chapter 6Product sales, revenue analysis by type and application from 2018 to 2029 in US & Canada. Product sales and revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product sales, revenue analysis by type and application from 2018 to 2029 in Europe. Product sales and revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product sales, revenue analysis by type and application from 2018 to 2029 in China. Product sales and revenue analysis of China from 2018 to 2029
Chapter 9Product sales, revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product sales and revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product sales, revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product sales and revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Manufacturers’ outline, covering company’s basic information, major business, Recombinant Insulin Analogue introduction, etc. Recombinant Insulin Analogue Sales, Revenue, Price and Gross Margin of each company from 2018 to 2024
Chapter 12Industry chain analysis, like raw materials, manufacturing cost. Market channel, distributors and customers analysis
Chapter 13Market opportunities and challenges analysis
Chapter 14Mr Accuracy reports Conclusions of Recombinant Insulin Analogue
Chapter 15Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Study Coverage
1.1 Recombinant Insulin Analogue Product Introduction
1.2 Market by Type
1.2.1 Global Recombinant Insulin Analogue Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Quick-Acting
1.2.3 Medium Effect
1.2.4 Long-Lasting
1.2.5 Super Long-Acting
1.3 Market by Application
1.3.1 Global Recombinant Insulin Analogue Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Type 1 Diabetes
1.3.3 Type 2 Diabetes
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global Recombinant Insulin Analogue Sales Estimates and Forecasts 2018-2029
2.2 Global Recombinant Insulin Analogue Revenue by Region
2.2.1 Global Recombinant Insulin Analogue Revenue by Region: 2018 VS 2022 VS 2029
2.2.2 Global Recombinant Insulin Analogue Revenue by Region (2018-2024)
2.2.3 Global Recombinant Insulin Analogue Revenue by Region (2024-2029)
2.2.4 Global Recombinant Insulin Analogue Revenue Market Share by Region (2018-2029)
2.3 Global Recombinant Insulin Analogue Sales Estimates and Forecasts 2018-2029
2.4 Global Recombinant Insulin Analogue Sales by Region
2.4.1 Global Recombinant Insulin Analogue Sales by Region: 2018 VS 2022 VS 2029
2.4.2 Global Recombinant Insulin Analogue Sales by Region (2018-2024)
2.4.3 Global Recombinant Insulin Analogue Sales by Region (2024-2029)
2.4.4 Global Recombinant Insulin Analogue Sales Market Share by Region (2018-2029)
2.5 US & Canada
2.6 Europe
2.7 China
2.8 Asia (excluding China)
2.9 Middle East, Africa and Latin America
3 Competition by Manufactures
3.1 Global Recombinant Insulin Analogue Sales by Manufacturers
3.1.1 Global Recombinant Insulin Analogue Sales by Manufacturers (2018-2024)
3.1.2 Global Recombinant Insulin Analogue Sales Market Share by Manufacturers (2018-2024)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Recombinant Insulin Analogue in 2022
3.2 Global Recombinant Insulin Analogue Revenue by Manufacturers
3.2.1 Global Recombinant Insulin Analogue Revenue by Manufacturers (2018-2024)
3.2.2 Global Recombinant Insulin Analogue Revenue Market Share by Manufacturers (2018-2024)
3.2.3 Global Top 10 and Top 5 Companies by Recombinant Insulin Analogue Revenue in 2022
3.3 Global Key Players of Recombinant Insulin Analogue, Industry Ranking, 2021 VS 2022 VS 2024
3.4 Global Recombinant Insulin Analogue Sales Price by Manufacturers
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Recombinant Insulin Analogue, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Recombinant Insulin Analogue, Product Offered and Application
3.8 Global Key Manufacturers of Recombinant Insulin Analogue, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Recombinant Insulin Analogue Sales by Type
4.1.1 Global Recombinant Insulin Analogue Historical Sales by Type (2018-2024)
4.1.2 Global Recombinant Insulin Analogue Forecasted Sales by Type (2024-2029)
4.1.3 Global Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
4.2 Global Recombinant Insulin Analogue Revenue by Type
4.2.1 Global Recombinant Insulin Analogue Historical Revenue by Type (2018-2024)
4.2.2 Global Recombinant Insulin Analogue Forecasted Revenue by Type (2024-2029)
4.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
4.3 Global Recombinant Insulin Analogue Price by Type
4.3.1 Global Recombinant Insulin Analogue Price by Type (2018-2024)
4.3.2 Global Recombinant Insulin Analogue Price Forecast by Type (2024-2029)
5 Market Size by Application
5.1 Global Recombinant Insulin Analogue Sales by Application
5.1.1 Global Recombinant Insulin Analogue Historical Sales by Application (2018-2024)
5.1.2 Global Recombinant Insulin Analogue Forecasted Sales by Application (2024-2029)
5.1.3 Global Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
5.2 Global Recombinant Insulin Analogue Revenue by Application
5.2.1 Global Recombinant Insulin Analogue Historical Revenue by Application (2018-2024)
5.2.2 Global Recombinant Insulin Analogue Forecasted Revenue by Application (2024-2029)
5.2.3 Global Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
5.3 Global Recombinant Insulin Analogue Price by Application
5.3.1 Global Recombinant Insulin Analogue Price by Application (2018-2024)
5.3.2 Global Recombinant Insulin Analogue Price Forecast by Application (2024-2029)
6 US & Canada
6.1 US & Canada Recombinant Insulin Analogue Market Size by Type
6.1.1 US & Canada Recombinant Insulin Analogue Sales by Type (2018-2029)
6.1.2 US & Canada Recombinant Insulin Analogue Revenue by Type (2018-2029)
6.2 US & Canada Recombinant Insulin Analogue Market Size by Application
6.2.1 US & Canada Recombinant Insulin Analogue Sales by Application (2018-2029)
6.2.2 US & Canada Recombinant Insulin Analogue Revenue by Application (2018-2029)
6.3 US & Canada Recombinant Insulin Analogue Market Size by Country
6.3.1 US & Canada Recombinant Insulin Analogue Revenue by Country: 2018 VS 2022 VS 2029
6.3.2 US & Canada Recombinant Insulin Analogue Sales by Country (2018-2029)
6.3.3 US & Canada Recombinant Insulin Analogue Revenue by Country (2018-2029)
6.3.4 US
6.3.5 Canada
7 Europe
7.1 Europe Recombinant Insulin Analogue Market Size by Type
7.1.1 Europe Recombinant Insulin Analogue Sales by Type (2018-2029)
7.1.2 Europe Recombinant Insulin Analogue Revenue by Type (2018-2029)
7.2 Europe Recombinant Insulin Analogue Market Size by Application
7.2.1 Europe Recombinant Insulin Analogue Sales by Application (2018-2029)
7.2.2 Europe Recombinant Insulin Analogue Revenue by Application (2018-2029)
7.3 Europe Recombinant Insulin Analogue Market Size by Country
7.3.1 Europe Recombinant Insulin Analogue Revenue by Country: 2018 VS 2022 VS 2029
7.3.2 Europe Recombinant Insulin Analogue Sales by Country (2018-2029)
7.3.3 Europe Recombinant Insulin Analogue Revenue by Country (2018-2029)
7.3.4 Germany
7.3.5 France
7.3.6 U.K.
7.3.7 Italy
7.3.8 Russia
8 China
8.1 China Recombinant Insulin Analogue Market Size
8.1.1 China Recombinant Insulin Analogue Sales (2018-2029)
8.1.2 China Recombinant Insulin Analogue Revenue (2018-2029)
8.2 China Recombinant Insulin Analogue Market Size by Application
8.2.1 China Recombinant Insulin Analogue Sales by Application (2018-2029)
8.2.2 China Recombinant Insulin Analogue Revenue by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Recombinant Insulin Analogue Market Size by Type
9.1.1 Asia Recombinant Insulin Analogue Sales by Type (2018-2029)
9.1.2 Asia Recombinant Insulin Analogue Revenue by Type (2018-2029)
9.2 Asia Recombinant Insulin Analogue Market Size by Application
9.2.1 Asia Recombinant Insulin Analogue Sales by Application (2018-2029)
9.2.2 Asia Recombinant Insulin Analogue Revenue by Application (2018-2029)
9.3 Asia Recombinant Insulin Analogue Sales by Region
9.3.1 Asia Recombinant Insulin Analogue Revenue by Region: 2018 VS 2022 VS 2029
9.3.2 Asia Recombinant Insulin Analogue Revenue by Region (2018-2029)
9.3.3 Asia Recombinant Insulin Analogue Sales by Region (2018-2029)
9.3.4 Japan
9.3.5 South Korea
9.3.6 China Taiwan
9.3.7 Southeast Asia
9.3.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Recombinant Insulin Analogue Market Size by Type
10.1.1 Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Type (2018-2029)
10.1.2 Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Type (2018-2029)
10.2 Middle East, Africa and Latin America Recombinant Insulin Analogue Market Size by Application
10.2.1 Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Application (2018-2029)
10.2.2 Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Application (2018-2029)
10.3 Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Country
10.3.1 Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Country: 2018 VS 2022 VS 2029
10.3.2 Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Country (2018-2029)
10.3.3 Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Country (2018-2029)
10.3.4 Brazil
10.3.5 Mexico
10.3.6 Turkey
10.3.7 Israel
10.3.8 GCC Countries
11 Company Profiles
11.1 Novo Nordisk A/S
11.1.1 Novo Nordisk A/S Company Information
11.1.2 Novo Nordisk A/S Overview
11.1.3 Novo Nordisk A/S Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.1.4 Novo Nordisk A/S Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Novo Nordisk A/S Recent Developments
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Information
11.2.2 Eli Lilly and Company Overview
11.2.3 Eli Lilly and Company Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.2.4 Eli Lilly and Company Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Eli Lilly and Company Recent Developments
11.3 Sanofi
11.3.1 Sanofi Company Information
11.3.2 Sanofi Overview
11.3.3 Sanofi Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.3.4 Sanofi Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Sanofi Recent Developments
11.4 Gan & Lee Pharmaceuticals Co., Ltd
11.4.1 Gan & Lee Pharmaceuticals Co., Ltd Company Information
11.4.2 Gan & Lee Pharmaceuticals Co., Ltd Overview
11.4.3 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.4.4 Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 Gan & Lee Pharmaceuticals Co., Ltd Recent Developments
11.5 The United Laboratories International Holdings Limited
11.5.1 The United Laboratories International Holdings Limited Company Information
11.5.2 The United Laboratories International Holdings Limited Overview
11.5.3 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.5.4 The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 The United Laboratories International Holdings Limited Recent Developments
11.6 Tonghua Dongbao Pharmaceutical Co., Ltd
11.6.1 Tonghua Dongbao Pharmaceutical Co., Ltd Company Information
11.6.2 Tonghua Dongbao Pharmaceutical Co., Ltd Overview
11.6.3 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales, Price, Revenue and Gross Margin (2018-2024)
11.6.4 Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Recombinant Insulin Analogue Industry Chain Analysis
12.2 Recombinant Insulin Analogue Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Recombinant Insulin Analogue Production Mode & Process
12.4 Recombinant Insulin Analogue Sales and Marketing
12.4.1 Recombinant Insulin Analogue Sales Channels
12.4.2 Recombinant Insulin Analogue Distributors
12.5 Recombinant Insulin Analogue Customers
13 Market Dynamics
13.1 Recombinant Insulin Analogue Industry Trends
13.2 Recombinant Insulin Analogue Market Drivers
13.3 Recombinant Insulin Analogue Market Challenges
13.4 Recombinant Insulin Analogue Market Restraints
14 Key Findings in The Global Recombinant Insulin Analogue Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Recombinant Insulin Analogue Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Table 2. Major Manufacturers of Quick-Acting
Table 3. Major Manufacturers of Medium Effect
Table 4. Major Manufacturers of Long-Lasting
Table 5. Major Manufacturers of Super Long-Acting
Table 6. Global Recombinant Insulin Analogue Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Table 7. Global Recombinant Insulin Analogue Revenue Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 8. Global Recombinant Insulin Analogue Revenue by Region (2018-2024) & (US$ Million)
Table 9. Global Recombinant Insulin Analogue Revenue by Region (2024-2029) & (US$ Million)
Table 10. Global Recombinant Insulin Analogue Revenue Market Share by Region (2018-2024)
Table 11. Global Recombinant Insulin Analogue Revenue Market Share by Region (2024-2029)
Table 12. Global Recombinant Insulin Analogue Sales Grow Rate (CAGR) by Region: 2018 VS 2022 VS 2029 (US$ Million)
Table 13. Global Recombinant Insulin Analogue Sales by Region (2018-2024) & (K Units)
Table 14. Global Recombinant Insulin Analogue Sales by Region (2024-2029) & (K Units)
Table 15. Global Recombinant Insulin Analogue Sales Market Share by Region (2018-2024)
Table 16. Global Recombinant Insulin Analogue Sales Market Share by Region (2024-2029)
Table 17. Global Recombinant Insulin Analogue Sales by Manufacturers (2018-2024) & (K Units)
Table 18. Global Recombinant Insulin Analogue Sales Share by Manufacturers (2018-2024)
Table 19. Global Recombinant Insulin Analogue Revenue by Manufacturers (2018-2024) & (US$ Million)
Table 20. Global Recombinant Insulin Analogue Revenue Share by Manufacturers (2018-2024)
Table 21. Global Key Players of Recombinant Insulin Analogue, Industry Ranking, 2021 VS 2022 VS 2024
Table 22. Recombinant Insulin Analogue Price by Manufacturers 2018-2024 (US$/Unit)
Table 23. Global Recombinant Insulin Analogue Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Recombinant Insulin Analogue by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recombinant Insulin Analogue as of 2022)
Table 25. Global Key Manufacturers of Recombinant Insulin Analogue, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Recombinant Insulin Analogue, Product Offered and Application
Table 27. Global Key Manufacturers of Recombinant Insulin Analogue, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Recombinant Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 30. Global Recombinant Insulin Analogue Sales by Type (2024-2029) & (K Units)
Table 31. Global Recombinant Insulin Analogue Sales Share by Type (2018-2024)
Table 32. Global Recombinant Insulin Analogue Sales Share by Type (2024-2029)
Table 33. Global Recombinant Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 34. Global Recombinant Insulin Analogue Revenue by Type (2024-2029) & (US$ Million)
Table 35. Global Recombinant Insulin Analogue Revenue Share by Type (2018-2024)
Table 36. Global Recombinant Insulin Analogue Revenue Share by Type (2024-2029)
Table 37. Recombinant Insulin Analogue Price by Type (2018-2024) & (US$/Unit)
Table 38. Global Recombinant Insulin Analogue Price Forecast by Type (2024-2029) & (US$/Unit)
Table 39. Global Recombinant Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 40. Global Recombinant Insulin Analogue Sales by Application (2024-2029) & (K Units)
Table 41. Global Recombinant Insulin Analogue Sales Share by Application (2018-2024)
Table 42. Global Recombinant Insulin Analogue Sales Share by Application (2024-2029)
Table 43. Global Recombinant Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 44. Global Recombinant Insulin Analogue Revenue by Application (2024-2029) & (US$ Million)
Table 45. Global Recombinant Insulin Analogue Revenue Share by Application (2018-2024)
Table 46. Global Recombinant Insulin Analogue Revenue Share by Application (2024-2029)
Table 47. Recombinant Insulin Analogue Price by Application (2018-2024) & (US$/Unit)
Table 48. Global Recombinant Insulin Analogue Price Forecast by Application (2024-2029) & (US$/Unit)
Table 49. US & Canada Recombinant Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 50. US & Canada Recombinant Insulin Analogue Sales by Type (2024-2029) & (K Units)
Table 51. US & Canada Recombinant Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 52. US & Canada Recombinant Insulin Analogue Revenue by Type (2024-2029) & (US$ Million)
Table 53. US & Canada Recombinant Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 54. US & Canada Recombinant Insulin Analogue Sales by Application (2024-2029) & (K Units)
Table 55. US & Canada Recombinant Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 56. US & Canada Recombinant Insulin Analogue Revenue by Application (2024-2029) & (US$ Million)
Table 57. US & Canada Recombinant Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 58. US & Canada Recombinant Insulin Analogue Revenue by Country (2018-2024) & (US$ Million)
Table 59. US & Canada Recombinant Insulin Analogue Revenue by Country (2024-2029) & (US$ Million)
Table 60. US & Canada Recombinant Insulin Analogue Sales by Country (2018-2024) & (K Units)
Table 61. US & Canada Recombinant Insulin Analogue Sales by Country (2024-2029) & (K Units)
Table 62. Europe Recombinant Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 63. Europe Recombinant Insulin Analogue Sales by Type (2024-2029) & (K Units)
Table 64. Europe Recombinant Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 65. Europe Recombinant Insulin Analogue Revenue by Type (2024-2029) & (US$ Million)
Table 66. Europe Recombinant Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 67. Europe Recombinant Insulin Analogue Sales by Application (2024-2029) & (K Units)
Table 68. Europe Recombinant Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 69. Europe Recombinant Insulin Analogue Revenue by Application (2024-2029) & (US$ Million)
Table 70. Europe Recombinant Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 71. Europe Recombinant Insulin Analogue Revenue by Country (2018-2024) & (US$ Million)
Table 72. Europe Recombinant Insulin Analogue Revenue by Country (2024-2029) & (US$ Million)
Table 73. Europe Recombinant Insulin Analogue Sales by Country (2018-2024) & (K Units)
Table 74. Europe Recombinant Insulin Analogue Sales by Country (2024-2029) & (K Units)
Table 75. China Recombinant Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 76. China Recombinant Insulin Analogue Sales by Type (2024-2029) & (K Units)
Table 77. China Recombinant Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 78. China Recombinant Insulin Analogue Revenue by Type (2024-2029) & (US$ Million)
Table 79. China Recombinant Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 80. China Recombinant Insulin Analogue Sales by Application (2024-2029) & (K Units)
Table 81. China Recombinant Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 82. China Recombinant Insulin Analogue Revenue by Application (2024-2029) & (US$ Million)
Table 83. Asia Recombinant Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 84. Asia Recombinant Insulin Analogue Sales by Type (2024-2029) & (K Units)
Table 85. Asia Recombinant Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 86. Asia Recombinant Insulin Analogue Revenue by Type (2024-2029) & (US$ Million)
Table 87. Asia Recombinant Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 88. Asia Recombinant Insulin Analogue Sales by Application (2024-2029) & (K Units)
Table 89. Asia Recombinant Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 90. Asia Recombinant Insulin Analogue Revenue by Application (2024-2029) & (US$ Million)
Table 91. Asia Recombinant Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 92. Asia Recombinant Insulin Analogue Revenue by Region (2018-2024) & (US$ Million)
Table 93. Asia Recombinant Insulin Analogue Revenue by Region (2024-2029) & (US$ Million)
Table 94. Asia Recombinant Insulin Analogue Sales by Region (2018-2024) & (K Units)
Table 95. Asia Recombinant Insulin Analogue Sales by Region (2024-2029) & (K Units)
Table 96. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Type (2018-2024) & (K Units)
Table 97. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Type (2024-2029) & (K Units)
Table 98. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Type (2018-2024) & (US$ Million)
Table 99. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Type (2024-2029) & (US$ Million)
Table 100. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Application (2018-2024) & (K Units)
Table 101. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Application (2024-2029) & (K Units)
Table 102. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Application (2018-2024) & (US$ Million)
Table 103. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Application (2024-2029) & (US$ Million)
Table 104. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue Grow Rate (CAGR) by Country: 2018 VS 2022 VS 2029 (US$ Million)
Table 105. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Country (2018-2024) & (US$ Million)
Table 106. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue by Country (2024-2029) & (US$ Million)
Table 107. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Country (2018-2024) & (K Units)
Table 108. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales by Country (2024-2029) & (K Units)
Table 109. Novo Nordisk A/S Company Information
Table 110. Novo Nordisk A/S Description and Major Businesses
Table 111. Novo Nordisk A/S Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 112. Novo Nordisk A/S Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 113. Novo Nordisk A/S Recent Developments
Table 114. Eli Lilly and Company Company Information
Table 115. Eli Lilly and Company Description and Major Businesses
Table 116. Eli Lilly and Company Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 117. Eli Lilly and Company Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 118. Eli Lilly and Company Recent Developments
Table 119. Sanofi Company Information
Table 120. Sanofi Description and Major Businesses
Table 121. Sanofi Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 122. Sanofi Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 123. Sanofi Recent Developments
Table 124. Gan & Lee Pharmaceuticals Co., Ltd Company Information
Table 125. Gan & Lee Pharmaceuticals Co., Ltd Description and Major Businesses
Table 126. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 127. Gan & Lee Pharmaceuticals Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 128. Gan & Lee Pharmaceuticals Co., Ltd Recent Developments
Table 129. The United Laboratories International Holdings Limited Company Information
Table 130. The United Laboratories International Holdings Limited Description and Major Businesses
Table 131. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 132. The United Laboratories International Holdings Limited Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 133. The United Laboratories International Holdings Limited Recent Developments
Table 134. Tonghua Dongbao Pharmaceutical Co., Ltd Company Information
Table 135. Tonghua Dongbao Pharmaceutical Co., Ltd Description and Major Businesses
Table 136. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2024)
Table 137. Tonghua Dongbao Pharmaceutical Co., Ltd Recombinant Insulin Analogue Product Model Numbers, Pictures, Descriptions and Specifications
Table 138. Tonghua Dongbao Pharmaceutical Co., Ltd Recent Developments
Table 139. Key Raw Materials Lists
Table 140. Raw Materials Key Suppliers Lists
Table 141. Recombinant Insulin Analogue Distributors List
Table 142. Recombinant Insulin Analogue Customers List
Table 143. Recombinant Insulin Analogue Market Trends
Table 144. Recombinant Insulin Analogue Market Drivers
Table 145. Recombinant Insulin Analogue Market Challenges
Table 146. Recombinant Insulin Analogue Market Restraints
Table 147. Research Programs/Design for This Report
Table 148. Key Data Information from Secondary Sources
Table 149. Key Data Information from Primary Sources
List of Figures
Figure 1. Recombinant Insulin Analogue Product Picture
Figure 2. Global Recombinant Insulin Analogue Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 3. Global Recombinant Insulin Analogue Market Share by Type in 2022 & 2029
Figure 4. Quick-Acting Product Picture
Figure 5. Medium Effect Product Picture
Figure 6. Long-Lasting Product Picture
Figure 7. Super Long-Acting Product Picture
Figure 8. Global Recombinant Insulin Analogue Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Recombinant Insulin Analogue Market Share by Application in 2022 & 2029
Figure 10. Type 1 Diabetes
Figure 11. Type 2 Diabetes
Figure 12. Recombinant Insulin Analogue Report Years Considered
Figure 13. Global Recombinant Insulin Analogue Revenue, (US$ Million), 2018 VS 2022 VS 2029
Figure 14. Global Recombinant Insulin Analogue Revenue 2018-2029 (US$ Million)
Figure 15. Global Recombinant Insulin Analogue Revenue Market Share by Region in Percentage: 2022 Versus 2029
Figure 16. Global Recombinant Insulin Analogue Revenue Market Share by Region (2018-2029)
Figure 17. Global Recombinant Insulin Analogue Sales 2018-2029 ((K Units)
Figure 18. Global Recombinant Insulin Analogue Sales Market Share by Region (2018-2029)
Figure 19. US & Canada Recombinant Insulin Analogue Sales YoY (2018-2029) & (K Units)
Figure 20. US & Canada Recombinant Insulin Analogue Revenue YoY (2018-2029) & (US$ Million)
Figure 21. Europe Recombinant Insulin Analogue Sales YoY (2018-2029) & (K Units)
Figure 22. Europe Recombinant Insulin Analogue Revenue YoY (2018-2029) & (US$ Million)
Figure 23. China Recombinant Insulin Analogue Sales YoY (2018-2029) & (K Units)
Figure 24. China Recombinant Insulin Analogue Revenue YoY (2018-2029) & (US$ Million)
Figure 25. Asia (excluding China) Recombinant Insulin Analogue Sales YoY (2018-2029) & (K Units)
Figure 26. Asia (excluding China) Recombinant Insulin Analogue Revenue YoY (2018-2029) & (US$ Million)
Figure 27. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales YoY (2018-2029) & (K Units)
Figure 28. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue YoY (2018-2029) & (US$ Million)
Figure 29. The Recombinant Insulin Analogue Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2022
Figure 30. The Top 5 and 10 Largest Manufacturers of Recombinant Insulin Analogue in the World: Market Share by Recombinant Insulin Analogue Revenue in 2022
Figure 31. Global Recombinant Insulin Analogue Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2022
Figure 32. Global Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
Figure 33. Global Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
Figure 34. Global Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
Figure 35. Global Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
Figure 36. US & Canada Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
Figure 37. US & Canada Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
Figure 38. US & Canada Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
Figure 39. US & Canada Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
Figure 40. US & Canada Recombinant Insulin Analogue Revenue Share by Country (2018-2029)
Figure 41. US & Canada Recombinant Insulin Analogue Sales Share by Country (2018-2029)
Figure 42. U.S. Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 43. Canada Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 44. Europe Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
Figure 45. Europe Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
Figure 46. Europe Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
Figure 47. Europe Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
Figure 48. Europe Recombinant Insulin Analogue Revenue Share by Country (2018-2029)
Figure 49. Europe Recombinant Insulin Analogue Sales Share by Country (2018-2029)
Figure 50. Germany Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 51. France Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 52. U.K. Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 53. Italy Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 54. Russia Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 55. China Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
Figure 56. China Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
Figure 57. China Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
Figure 58. China Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
Figure 59. Asia Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
Figure 60. Asia Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
Figure 61. Asia Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
Figure 62. Asia Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
Figure 63. Asia Recombinant Insulin Analogue Revenue Share by Region (2018-2029)
Figure 64. Asia Recombinant Insulin Analogue Sales Share by Region (2018-2029)
Figure 65. Japan Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 66. South Korea Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 67. China Taiwan Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 68. Southeast Asia Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 69. India Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 70. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales Market Share by Type (2018-2029)
Figure 71. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue Market Share by Type (2018-2029)
Figure 72. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales Market Share by Application (2018-2029)
Figure 73. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue Market Share by Application (2018-2029)
Figure 74. Middle East, Africa and Latin America Recombinant Insulin Analogue Revenue Share by Country (2018-2029)
Figure 75. Middle East, Africa and Latin America Recombinant Insulin Analogue Sales Share by Country (2018-2029)
Figure 76. Brazil Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 77. Mexico Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 78. Turkey Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 79. Israel Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 80. GCC Countries Recombinant Insulin Analogue Revenue (2018-2029) & (US$ Million)
Figure 81. Recombinant Insulin Analogue Value Chain
Figure 82. Recombinant Insulin Analogue Production Process
Figure 83. Channels of Distribution
Figure 84. Distributors Profiles
Figure 85. Bottom-up and Top-down Approaches for This Report
Figure 86. Data Triangulation
Figure 87. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries